Mermaid Medical Group, a privately-owned international provider of minimally invasive medical devices, acknowledged a product line addition to its vascular business. As part of its strategic focus for expanding their vascular product portfolio, Mermaid Medical Group announced the acquisition of the Angel Catheter technology from Bio2 Medical Inc.
The acquisition establishes Mermaid Medical’s presence in the vascular business, adding a clinically proven and current commercialised product. The Angel catheter can minimise the incidence of pulmonary embolism (PE) by utilising a “temporary” catheter with an attached nitinol basket placed in the femoral vein. Bedside placement allows for easier, quicker, placement while minimising hospital costs.
The Angel catheter offers a safe, effective alternative for catching potential thrombus due to trauma and various underlying patient disease states. The Angel catheter will be utilised throughout the hospital where patients are at risk of a pulmonary embolism.
“The addition of the Angel catheter with its present indication and extensive related portfolio of intellectual property will add significant value to our company” said Lars Vinther, president and CEO of the Mermaid Medical Group. “It will also enhance our strength going forward supporting our upcoming Mechanically Thrombectomy System D-Clot, and will also open new doors at the Trauma units.”
Approved by the FDA in June 2015, the Angel catheter became commercially available in January 2017. The Mermaid Medical Group will immediately begin supporting the current Angel customer base worldwide, with plans to expand the product offering to additional existing Mermaid Medical global markets.
